The patent covers the formulation of pain drug Opana ER (oxymorphone HCl) extended-release tablets CII using Penwest’s TIMERx technology and is exclusively licensed to Endo Pharmaceuticals pursuant to the contract governing the company’s collaboration with Endo for Opana ER. Endo has submitted this patent for listing in the Orange Book, published by the FDA.
Jennifer Good, president and CEO of Penwest, said: “We are very pleased that this patent has now been formally issued by the USPTO and submitted for listing in the Orange Book. We believe that this patent, which expires in 2023, strengthens the intellectual property protection for Opana ER.”